[1] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[2] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
[3] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
[4] |
GUO Yijun, CHEN Xia, MENG Ping.
Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
|
[5] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[6] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[7] |
LUO Shishu, QU Jie, ZHOU Nan, XU Cuixiang, LIU Yi, ZHANG Lijie, WANG Jianhua.
289 cases of adverse drug reactions associated with monoclonal antibody antitumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 444-448.
|
[8] |
HUNG Ping, WANG Tie-zhu, GE Wen-chao .
Related Factors Analysis of Vomiting Caused by Commonly Used Antineoplastic
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(5): 306-308.
|
[9] |
.
[J]. Chinese Journal of Pharmacovigilance, 2010, 7(12): 761-761.
|
[10] |
.
[J]. Chinese Journal of Pharmacovigilance, 2010, 7(9): 572-572.
|